LUNG logo

Pulmonx (LUNG) Company Overview

Profile

Full Name:

Pulmonx Corporation

Sector:

Healthcare

Country:

United States

IPO:

October 1, 2020

Indexes:

Not included

Description:

LUNG (Pulmonx) is a medical company that focuses on innovative treatments for lung diseases. They develop advanced technologies to help patients with conditions like emphysema. Their main product, the Zephyr Valve, improves breathing by reducing lung volume and enhancing airflow, leading to better quality of life for patients.

Events Calendar

Earnings

Next earnings date:

Feb 21, 2025

Recent quarterly earnings:

Oct 30, 2024

Recent annual earnings:

Feb 21, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

Dec 11, 24 Wells Fargo
Equal-Weight
Dec 11, 24 Citigroup
Neutral
Oct 31, 24 Stifel
Buy
Aug 1, 24 Wells Fargo
Equal-Weight
Aug 1, 24 Piper Sandler
Overweight
Aug 1, 24 Canaccord Genuity
Buy
Jun 4, 24 Lake Street
Buy
May 2, 24 Canaccord Genuity
Buy
Apr 3, 24 Piper Sandler
Overweight
Feb 23, 24 Wells Fargo
Equal-Weight

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

Pulmonx Corporation (LUNG) Reports Q3 Loss, Misses Revenue Estimates
Pulmonx Corporation (LUNG) Reports Q3 Loss, Misses Revenue Estimates
Pulmonx Corporation (LUNG) Reports Q3 Loss, Misses Revenue Estimates
LUNG
zacks.comOctober 30, 2024

Pulmonx Corporation (LUNG) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to loss of $0.39 per share a year ago.

AMGEN PRESENTS NEW DATA FOR FIRST-IN-CLASS IMDELLTRA™ (TARLATAMAB-DLLE) IN SMALL CELL LUNG CANCER AT WCLC 2024
AMGEN PRESENTS NEW DATA FOR FIRST-IN-CLASS IMDELLTRA™ (TARLATAMAB-DLLE) IN SMALL CELL LUNG CANCER AT WCLC 2024
AMGEN PRESENTS NEW DATA FOR FIRST-IN-CLASS IMDELLTRA™ (TARLATAMAB-DLLE) IN SMALL CELL LUNG CANCER AT WCLC 2024
LUNG
prnewswire.comSeptember 9, 2024

DeLLphi-303 Study Results Show Potential for IMDELLTRA in Combination with a PD-L1 Inhibitor as First-Line Maintenance Therapy in ES-SCLC DeLLphi-301 Long-Term Follow-up Data Demonstrate Sustained Safety and Efficacy for IMDELLTRA THOUSAND OAKS, Calif. , Sept. 9, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the presentation of new data showcasing IMDELLTRATM (tarlatamab-dlle), a first-in-class delta-like ligand 3 (DLL3)-targeting Bispecific T-cell Engager (BiTE®) molecule, at the 2024 World Conference on Lung Cancer (WCLC) in San Diego.

Pulmonx to Participate in the Lake Street 8th Annual Best Ideas Growth Conference
Pulmonx to Participate in the Lake Street 8th Annual Best Ideas Growth Conference
Pulmonx to Participate in the Lake Street 8th Annual Best Ideas Growth Conference
LUNG
globenewswire.comAugust 29, 2024

REDWOOD CITY, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in investor meetings at the Lake Street 8th Annual Best Ideas Growth Conference in New York on Thursday, September 14, 2024.

Pulmonx to Present at the 2024 Wells Fargo Healthcare Conference
Pulmonx to Present at the 2024 Wells Fargo Healthcare Conference
Pulmonx to Present at the 2024 Wells Fargo Healthcare Conference
LUNG
globenewswire.comAugust 22, 2024

REDWOOD CITY, Calif., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in a fireside chat at the 2024 Wells Fargo Healthcare Conference in Boston on Thursday, September 5, 2024, at 1:30 PM PT / 4:30 PM ET.

Pulmonx Corporation (LUNG) Reports Q2 Loss, Tops Revenue Estimates
Pulmonx Corporation (LUNG) Reports Q2 Loss, Tops Revenue Estimates
Pulmonx Corporation (LUNG) Reports Q2 Loss, Tops Revenue Estimates
LUNG
zacks.comJuly 31, 2024

Pulmonx Corporation (LUNG) came out with a quarterly loss of $0.39 per share versus the Zacks Consensus Estimate of a loss of $0.41. This compares to loss of $0.43 per share a year ago.

Pulmonx Reports Second Quarter 2024 Financial Results
Pulmonx Reports Second Quarter 2024 Financial Results
Pulmonx Reports Second Quarter 2024 Financial Results
LUNG
globenewswire.comJuly 31, 2024

REDWOOD CITY, Calif., July 31, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the second quarter of 2024 ended June 30, 2024.

Pulmonx to Present at the Canaccord Genuity 44th Annual Growth Conference
Pulmonx to Present at the Canaccord Genuity 44th Annual Growth Conference
Pulmonx to Present at the Canaccord Genuity 44th Annual Growth Conference
LUNG
globenewswire.comJuly 29, 2024

REDWOOD CITY, Calif., July 29, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for severe lung disease, today announced the company will present at the upcoming Canaccord Genuity 44th Annual Growth Conference in Boston. Management is scheduled to present on Tuesday, August 13, 2024, at 5:00 AM PT / 8:00 AM ET.

Pulmonx: Low Bar For Q2 Earnings
Pulmonx: Low Bar For Q2 Earnings
Pulmonx: Low Bar For Q2 Earnings
LUNG
seekingalpha.comJuly 21, 2024

New CEO suggests status quo with respect to corporate strategy. Upcoming Q2 earnings have low expectations, which could provide a short-term positive catalyst. However, longer-term, the main issue with Pulmonx remains the mismatch between revenues and expenses.

Pulmonx to Report Second Quarter 2024 Financial Results on July 31, 2024
Pulmonx to Report Second Quarter 2024 Financial Results on July 31, 2024
Pulmonx to Report Second Quarter 2024 Financial Results on July 31, 2024
LUNG
globenewswire.comJuly 10, 2024

REDWOOD CITY, Calif., July 10, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the second quarter of 2024 after the close of trading on Wednesday, July 31, 2024. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET.

How Much Upside is Left in Pulmonx (LUNG)? Wall Street Analysts Think 80.3%
How Much Upside is Left in Pulmonx (LUNG)? Wall Street Analysts Think 80.3%
How Much Upside is Left in Pulmonx (LUNG)? Wall Street Analysts Think 80.3%
LUNG
zacks.comMay 22, 2024

The consensus price target hints at an 80.3% upside potential for Pulmonx (LUNG). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

  • 1(current)
  • 2
  • 3
  • 1(current)
  • 2
  • 3

FAQ

  • What is the ticker symbol for Pulmonx?
  • Does Pulmonx pay dividends?
  • What sector is Pulmonx in?
  • What industry is Pulmonx in?
  • What country is Pulmonx based in?
  • When did Pulmonx go public?
  • Is Pulmonx in the S&P 500?
  • Is Pulmonx in the NASDAQ 100?
  • Is Pulmonx in the Dow Jones?
  • When was Pulmonx's last earnings report?
  • When does Pulmonx report earnings?
  • Should I buy Pulmonx stock now?

What is the ticker symbol for Pulmonx?

The ticker symbol for Pulmonx is NASDAQ:LUNG

Does Pulmonx pay dividends?

No, Pulmonx does not pay dividends

What sector is Pulmonx in?

Pulmonx is in the Healthcare sector

What industry is Pulmonx in?

Pulmonx is in the Medical Devices industry

What country is Pulmonx based in?

Pulmonx is headquartered in United States

When did Pulmonx go public?

Pulmonx's initial public offering (IPO) was on October 1, 2020

Is Pulmonx in the S&P 500?

No, Pulmonx is not included in the S&P 500 index

Is Pulmonx in the NASDAQ 100?

No, Pulmonx is not included in the NASDAQ 100 index

Is Pulmonx in the Dow Jones?

No, Pulmonx is not included in the Dow Jones index

When was Pulmonx's last earnings report?

Pulmonx's most recent earnings report was on Oct 30, 2024

When does Pulmonx report earnings?

The next expected earnings date for Pulmonx is Feb 21, 2025

Should I buy Pulmonx stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions